CervoMed Inc.
CRVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.10 | 0.02 | 0.07 |
| FCF Yield | -87.51% | -36.69% | -65.42% | -47.91% |
| EV / EBITDA | -0.54 | -5.76 | -2.11 | -0.12 |
| Quality | ||||
| ROIC | -46.49% | -105.91% | -101.75% | -40.36% |
| Gross Margin | -93.04% | -18.11% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.01 | 3.43 | 0.44 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -121.89% | -189.57% | 82.26% | -7.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 3.59 | -1.43 | 1.12 |
| Interest Coverage | 0.00 | 0.00 | -5,921.64 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 55.15 | 18.11 | -26.58 | -3,702.10 |